Clinical Trial Update: Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluating blinatumomab for relapsed/refractory or MRD-positive CD19-positive mixed phenotype acute leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mixed Phenotype Acute Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD) | Phase 2 | Status: COMPLETED